PO.BCS01.06 · 生物信息与计算

利用基于空间转录组学指导的深度学习对肝细胞癌进行组织学分层

Histologic stratification of hepatocellular carcinoma using deep learning informed by spatial transcriptomics

海报缩略图:利用基于空间转录组学指导的深度学习对肝细胞癌进行组织学分层
编号 90 展板 21 时间 4/19 02:00–05:00 区域 Section 4 主讲 Tyler Yasaka, BS
分会场 Digital Pathology 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Tyler M. Yasaka1, Chang Kyung (Joanna) Kim1, Po-Yuan Chen1, Rebekah E. Dadey1, Riyue Bao1, Satdarshan Pal S. Monga2, Yu-Chiao Chiu3

1University of Pittsburgh, Pittsburgh, PA,2Associate Professor of Pathology & Med., University of Pittsburgh, Pittsburgh, PA,3UPMC Hillman Cancer Center, Pittsburgh, PA

摘要 Abstract

中文摘要
引言:肝细胞癌(HCC)是癌症相关死亡的主要原因之一。尽管已开发出多种分类系统,但其临床效用仍然有限。随着组织活检在靶向治疗试验中的应用日益增多,出现了推进HCC分层的分子和组织学方法的机会。 方法:使用来自10张HCC切片的公开可用空间转录组学数据及配对苏木精-伊红(H&E)图像,训练深度学习模型,从对应的H&E瓦片预测空间转录组学位点内的Hoshida亚型(S1、S2、S3)特征。模型采用80/20训练/测试划分进行评估,随后应用于来自癌症基因组图谱(TCGA;n=340)以及一个内部验证队列(n=48)的H&E全切片图像。将瓦片级预测汇总以生成患者级组织学评分,然后将其聚类为三个亚类(A、B和C),随后评估其独特的临床和分子特征。 结果:模型取得的留出AUROC分别为0.93(S1)、0.92(S2)和0.94(S3)。在TCGA中,亚类可预测总生存期(A对B,p<0.0001;A对C,p<0.0001)、无病间期(A对B,p<0.001;A对C,p<0.0001)和无进展间期(A对B,p<0.01;A对C,p<0.0001)。通过逐步Cox比例风险模型将组织学亚型与临床变量一同考量时,其为独立预后因素(A对B,p=0.008;A对C,p=0.001)。每个聚类与不同的临床特征(例如,聚类A与早期病理分期和HBV病因,聚类B与晚期)、突变和富集通路(聚类A与代谢通路,聚类B与细胞周期通路,聚类C与免疫通路)相关。聚类C还富集了HCC中抗PD-1反应的特征(p<1x10-10)。在验证队列中,总生存期趋势得以维持(A对B,p=0.121,A对C,p=0.005)。 结论:利用一个从H&E全切片图像预测空间亚型特征的深度学习模型,我们开发了一种基于组织学的分层方法,相较现有HCC亚型具有更强的预后能力。相关的临床和分子特征表明,这些亚型不仅表现出不同的表型(代谢、增殖和免疫),还可能具有不同的发病机制,支持H&E在临床试验中指导患者分层并为个体化治疗策略提供参考的潜力。
查看英文原文 English abstract
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Although multiple classification systems have been developed, their clinical utility remains limited. With the increasing use of tissue biopsies in targeted therapy trials, there is an opportunity to advance both molecular and histologic approaches for HCC stratification. Methods: Publicly available spatial transcriptomics data with paired hematoxylin and eosin (H&E) images from 10 HCC slides were used to train deep learning models to predict Hoshida subtype (S1, S2, S3) signatures within spatial transcriptomics spots from corresponding H&E tiles. Models were evaluated using an 80/20 training/test split and subsequently applied to H&E whole-slide images from The Cancer Genome Atlas (TCGA; n=340) as well as an in-house validation cohort (n=48). Tile-level predictions were aggregated to generate patient-level histologic scores, which were then clustered into three subclasses (A, B, and C), which were then assessed for unique clinical and molecular characteristics. Results: Models achieved holdout AUROCs of 0.93 (S1), 0.92 (S2), and 0.94 (S3). In TCGA, subclasses predicted overall survival (A vs B, p<0.0001; A vs C, p<0.0001), disease-free interval (A vs B, p<0.001; A vs C, p<0.0001), and progression-free interval (A vs B, p<0.01; A vs C, p<0.0001). Histologic subtypes were independently prognostic when considered alongside clinical variables via stepwise Cox proportional hazards (A vs B, p=0.008; A vs C, p=0.001). Each cluster associated with distinct clinical features (e.g. cluster A with early pathologic stage and HBV etiology, and cluster B with late stage), mutations, and enriched pathways (cluster A with metabolic pathways, cluster B with cell cycle pathways, and cluster C with immune pathways). Cluster C was also enriched for a signature of anti-PD-1 response in HCC (p<1x10-10). In the validation cohort, overall survival trends were maintained (A vs B, p=0.121, A vs C, p=0.005). Conclusions: Using a deep learning model which predicts spatial subtype signatures from H&E whole slide images, we developed a histology-based stratification with improved prognostic power compared to existing HCC subtypes. The associated clinical and molecular features suggest that these subtypes exhibit not only distinct phenotypes (metabolic, proliferative, and immune) but also potentially pathogenesis, supporting the potential of H&E to guide patient stratification in clinical trials and inform personalized therapeutic strategies.
利益披露 Disclosure
T. M. Yasaka, None.. C. Kim, None.. P. Chen, None.. R. E. Dadey, None.. R. Bao, None.

← 返回 AACR 2026 检索